Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2001 1
2002 1
2003 2
2006 4
2007 1
2008 1
2009 2
2010 2
2011 1
2012 3
2013 1
2014 2
2015 2
2016 5
2017 5
2018 2
2019 4
2020 7
2021 4
Text availability
Article attribute
Article type
Publication date

Search Results

47 results
Results by year
Filters applied: . Clear all
Page 1
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Bladé J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, von Lilienfeld-Toal M, Lonial S, Morgan GJ, Orlowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA; International Myeloma Working Group. Palumbo A, et al. Among authors: zonder ja. Leukemia. 2008 Feb;22(2):414-23. doi: 10.1038/sj.leu.2405062. Epub 2007 Dec 20. Leukemia. 2008. PMID: 18094721 Review.
The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG).
Kyriakou C, Molloy S, Vrionis F, Alberico R, Bastian L, Zonder JA, Giralt S, Raje N, Kyle RA, Roodman DGD, Dimopoulos MA, Rajkumar SV, Durie BBG, Terpos E. Kyriakou C, et al. Among authors: zonder ja. Blood Cancer J. 2019 Feb 26;9(3):27. doi: 10.1038/s41408-019-0187-7. Blood Cancer J. 2019. PMID: 30808868 Free PMC article.
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
Kumar SK, Jacobus SJ, Cohen AD, Weiss M, Callander N, Singh AK, Parker TL, Menter A, Yang X, Parsons B, Kumar P, Kapoor P, Rosenberg A, Zonder JA, Faber E Jr, Lonial S, Anderson KC, Richardson PG, Orlowski RZ, Wagner LI, Rajkumar SV. Kumar SK, et al. Among authors: zonder ja. Lancet Oncol. 2020 Oct;21(10):1317-1330. doi: 10.1016/S1470-2045(20)30452-6. Epub 2020 Aug 28. Lancet Oncol. 2020. PMID: 32866432 Clinical Trial.
INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma.
Costello C, Davies FE, Cook G, Vela-Ojeda J, Omel J, Rifkin RM, Berdeja J, Puig N, Usmani SZ, Weisel K, Zonder JA, Terpos E, Spencer A, Leleu X, Boccadoro M, Thompson MA, Romanus D, Stull DM, Hungria V. Costello C, et al. Among authors: zonder ja. Future Oncol. 2019 May;15(13):1411-1428. doi: 10.2217/fon-2019-0013. Epub 2019 Feb 28. Future Oncol. 2019. PMID: 30816809 Free PMC article.
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
Jakubowiak AJ, Jasielec JK, Rosenbaum CA, Cole CE, Chari A, Mikhael J, Nam J, McIver A, Severson E, Stephens LA, Tinari K, Rosebeck S, Zimmerman TM, Hycner T, Turowski A, Karrison T, Zonder JA. Jakubowiak AJ, et al. Among authors: zonder ja. Br J Haematol. 2019 Aug;186(4):549-560. doi: 10.1111/bjh.15969. Epub 2019 May 24. Br J Haematol. 2019. PMID: 31124580 Free PMC article. Clinical Trial.
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.
Usmani SZ, Hoering A, Ailawadhi S, Sexton R, Lipe B, Hita SF, Valent J, Rosenzweig M, Zonder JA, Dhodapkar M, Callander N, Zimmerman T, Voorhees PM, Durie B, Rajkumar SV, Richardson PG, Orlowski RZ; SWOG1211 Trial Investigators. Usmani SZ, et al. Among authors: zonder ja. Lancet Haematol. 2021 Jan;8(1):e45-e54. doi: 10.1016/S2352-3026(20)30354-9. Epub 2020 Dec 22. Lancet Haematol. 2021. PMID: 33357482 Clinical Trial.
The Spectrum of Monoclonal Immunoglobulin-Associated Diseases.
Tuchman SA, Zonder JA. Tuchman SA, et al. Among authors: zonder ja. Hematol Oncol Clin North Am. 2020 Dec;34(6):997-1008. doi: 10.1016/j.hoc.2020.07.002. Epub 2020 Oct 1. Hematol Oncol Clin North Am. 2020. PMID: 33099435 Review.
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.
Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, Dispenzieri A, Jaccard A, Schönland SO, Berg D, Yang H, Gupta N, Hui AM, Comenzo RL, Merlini G. Sanchorawala V, et al. Among authors: zonder ja. Blood. 2017 Aug 3;130(5):597-605. doi: 10.1182/blood-2017-03-771220. Epub 2017 May 26. Blood. 2017. PMID: 28550039 Free PMC article. Clinical Trial.
Exportin 1 inhibition as antiviral therapy.
Uddin MH, Zonder JA, Azmi AS. Uddin MH, et al. Among authors: zonder ja. Drug Discov Today. 2020 Jun 20;25(10):1775-81. doi: 10.1016/j.drudis.2020.06.014. Online ahead of print. Drug Discov Today. 2020. PMID: 32569833 Free PMC article.
47 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page